Business Context and Reporting Period
Company: Hercules Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2019
Business Overview: Hercules is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It focuses on providing senior secured loans, structured debt with warrants, and equity investments to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 |
|---|---|---|
| Total Investment Income | $128.1 million | $98.3 million |
| Net Investment Income | $64.3 million | $48.8 million |
| Net Realized Gain (Loss) | $8.8 million | ($13.8 million) |
| Net Unrealized Appreciation (Depreciation) | $36.6 million | $23.0 million |
| Net Increase in Net Assets from Operations | $109.7 million | $58.0 million |
| Net Asset Value (NAV) per Share | $10.59 | $9.90 (Dec 31, 2018) |
| Total Assets | $2.31 billion | $1.95 billion (Dec 31, 2018) |
| Total Liabilities | $1.21 billion | $0.99 billion (Dec 31, 2018) |
| Weighted Average Debt Outstanding | $1.12 billion | $0.81 billion |
| Portfolio Turnover Rate | 14.72% | 28.31% |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio fair value increased to $2.25 billion from $1.88 billion at year-end 2018, driven by new fundings of approximately $607.8 million.
- Income Growth: Net investment income increased 31.7% year-over-year, primarily due to a larger loan portfolio and fee accelerations from early repayments.
- Realized Gains: The company reported a net realized gain of $8.8 million for the six months ended June 30, 2019, a significant improvement from a net realized loss of $13.8 million in the same period in 2018. This was driven by sales of public equity holdings and M&A transactions.
- Debt Structure: The company issued $250 million in 2028 Asset-Backed Notes in January 2019 and fully repaid the $83.5 million 2024 Notes in early 2019. Total borrowings increased to $1.19 billion.
- Operating Expenses: Total operating expenses rose to $63.8 million from $49.4 million, driven by higher interest expense on new debt issuances and increased employee compensation.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted a strong origination pipeline with $177.2 million in unfunded commitments and $40.0 million in non-binding term sheets. The core yield on debt investments remained stable at 12.7%.
- Liquidity: As of June 30, 2019, the company had $194.9 million in available liquidity, including $13.3 million in cash and cash equivalents and significant capacity under credit facilities ($63.9 million Wells Facility, $117.7 million Union Bank Facility).
- Dividends: The Board declared a quarterly distribution of $0.33 per share for the quarter ended June 30, 2019. A subsequent distribution of $0.32 per share plus a $0.02 supplemental distribution was declared in July 2019.
- Risks and Contingencies:
- Valuation Risk: Approximately 97.4% of assets are Level 3 investments valued in good faith by the Board, which may differ from market values if a liquid market existed.
- Credit Risk: Four debt investments were on non-accrual status with a fair value of $4.8 million.
- Concentration: The portfolio is concentrated in Drug Discovery & Development (28.7%) and Software (26.8%).
- Leadership Transition: Subsequent to the period end, the company announced the departure of its Chairman and CEO, Manuel Henriquez, and the appointment of Scott Bluestein as CEO.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the current trading price of HTGC relative to the reported NAV of $10.59 to assess the discount/premium.
- Debt Maturity Wall: Review the maturity schedule of the $1.19 billion in borrowings, specifically the 2022 Notes ($150M) and 2022 Convertible Notes ($230M).
- Unfunded Commitments: Confirm the funding status of the $177.2 million in unfunded commitments, particularly for top borrowers like SeatGeek ($45M) and Tricida ($35M).
- Non-Accrual Status: Monitor the performance of the four portfolio companies currently on non-accrual status to assess potential future write-offs.
- Equity Offering Capacity: Verify the remaining capacity under the At-The-Market (ATM) equity distribution agreement, which stood at approximately 10.7 million shares as of June 30, 2019.